SAANGEN DEVELOPMENT PIPELINE

Therapies with a Difference

DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)

DCTR3128

DIPG or Diffuse Intrinsic Pontine Glioma is the most aggressive Cancer in the world. The prognosis of this disease is zero, due to the lack of any concrete drug therapy. The only available therapy is radiation which also is palliative. The disease occurs in childrens and statistics make DIPG one of the most devastating pediatric cancers. The median survival rate is just 9 months or lower. Survival upto 5 years is >1%. DCTR3128 is a small molecule and a potent glycolytic inhibitor which is been developed to target DIPG and to arrest the progress of the disease in combination with radiation. Our preclinical studies are ongoing at the moment and we hope to take this molecule to the patients at the earliest possible.

HEPATOCELLULAR ONCOLOGY

DCTR3128

We are currently developing a precision engineered, proprietary investigational new drug for the treatment of Hepatocellular Cancer or Liver Cancer. The drug is code named (DCTR3128) an already existing compound, in a highly effective, exciting proprietary form. HCC do not have much of treatment options available, and we believe that this investigational new drug will soon be an effective second chance, to those in need of a better option. The development of this drug is underway at the moment in Preclinical Stages with ground breaking results

GYNAECOLOGY

DCTR3128

Endometriosis is a painful condition of the uterus. millions of young women in the fertile age across the world. As part of our core focus on women healthcare apart from Oncology, we are developing a successful therapy for endometriosis. There is a lack of a safe non-hormonal, effective, therapy for this disease. Our proprietary molecule DCTR3128 is also focussed for this area of therapy since the compound has a vast and broad mechanism of action in cell biology.

DIPG is a type of brain cancer diagnosed in children in the age group of 3-10 years with a median overall survival of just 9 months. It is termed as the most aggressive Cancer in the world and there are no effective medical therapy options at the moment. DIPG is 100% fatal after diagnosis. Our molecule is undergoing further testings in Canberra and Sydney, Australia with our research collaborators, after initial highly promising test results in India.

Liver and Lung cancer, on the other hand, is among the top 5 killers and afflicts adult population the most. Our research product DCTR3128 is also undergoing further testing in India for Liver Cancer.

Our research products ARSP2831 AND DCTR3128 will be further undergoing testings with our research collaborators in Edinburgh, UK.

DCTR3128 is our answer to DIPG and other childhood Glioma or Brain Cancer. It is a small molecule easily crosses into the brain and the site of action. ARSP2831, on the other hand, is another potent investigational drug which is been currently tested for Lung Cancer and Liver Cancer.

To get this research products into the market Saangen is search of further funds and investments.

PULMONARY ONCOLOGY

ARSP2831

We are currently working on a proprietary formulation development of a known compound, which has shown very promising effects in preclinical POC stage, in the area of Lung Cancer. The drug is code named ARSP2831 and is been tested in Non-small cell Lung Cancer ( NSCLC). NSCLC is one of the foremost killers in Cancer related mortality. The therapy is in Preclinical stages and has shown highly motivating evidence in fighting NSCLC. Our effort is to develop a novel combination of a new drug and one of its kind delivery system in this therapy area.